These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12121939)

  • 1. Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus.
    Ono-Nita SK; Kato N; Shiratori Y; Carrilho FJ; Omata M
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2602-5. PubMed ID: 12121939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.
    Ono-Nita SK; Kato N; Shiratori Y; Lan KH; Yoshida H; Carrilho FJ; Omata M
    J Clin Invest; 1999 Jun; 103(12):1635-40. PubMed ID: 10377169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.
    Ono SK; Kato N; Shiratori Y; Kato J; Goto T; Schinazi RF; Carrilho FJ; Omata M
    J Clin Invest; 2001 Feb; 107(4):449-55. PubMed ID: 11181644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance.
    Gutfreund KS; Williams M; George R; Bain VG; Ma MM; Yoshida EM; Villeneuve JP; Fischer KP; Tyrrel DL
    J Hepatol; 2000 Sep; 33(3):469-75. PubMed ID: 11020004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives for the treatment of hepatitis B virus infections.
    De Clercq E
    Int J Antimicrob Agents; 1999 Jul; 12(2):81-95. PubMed ID: 10418752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subclones of drug-resistant hepatitis B virus mutants and the outcome of breakthrough hepatitis in patients treated with lamivudine.
    Kumashiro R; Kuwahara R; Ide T; Koga Y; Arinaga T; Hisamochi A; Ogata K; Tanaka K; Sata M
    Intervirology; 2003; 46(6):350-4. PubMed ID: 14688451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.
    Fu L; Cheng YC
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3402-7. PubMed ID: 11083647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel nucleoside analogue FNC is effective against both wild-type and lamivudine-resistant HBV clinical isolates.
    Zhou Y; Zhang Y; Yang X; Zhao J; Zheng L; Sun C; Jiang J; Yang Q; Wang Q; Chang J
    Antivir Ther; 2012; 17(8):1593-9. PubMed ID: 22910281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.
    Delaney WE; Miller TG; Isom HC
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2017-26. PubMed ID: 10428929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.
    Levine S; Hernandez D; Yamanaka G; Zhang S; Rose R; Weinheimer S; Colonno RJ
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2525-32. PubMed ID: 12121928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene.
    Torresi J; Earnest-Silveira L; Civitico G; Walters TE; Lewin SR; Fyfe J; Locarnini SA; Manns M; Trautwein C; Bock TC
    Virology; 2002 Jul; 299(1):88-99. PubMed ID: 12167344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
    Ben-Ari Z; Daudi N; Klein A; Sulkes J; Papo O; Mor E; Samra Z; Gadba R; Shouval D; Tur-Kaspa R
    Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.
    Yatsuji H; Noguchi C; Hiraga N; Mori N; Tsuge M; Imamura M; Takahashi S; Iwao E; Fujimoto Y; Ochi H; Abe H; Maekawa T; Tateno C; Yoshizato K; Suzuki F; Kumada H; Chayama K
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3867-74. PubMed ID: 16982790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine-resistant HBV isolate.
    Zhang Y; Zhang H; Zhang J; Zhang J; Guo H
    Antiviral Res; 2019 May; 165():47-54. PubMed ID: 30902704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates.
    Zhou YB; Wang YF; Zhang Y; Zheng LY; Yang XA; Wang N; Jiang JH; Ma F; Yin DT; Sun CY; Wang QD
    Eur J Pharmacol; 2012 May; 683(1-3):10-5. PubMed ID: 22387093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy.
    Zhang X; Liu C; Gong Q; Zhang S; Zhang D; Lu Z; Wang Y
    J Gastroenterol Hepatol; 2003 Dec; 18(12):1353-7. PubMed ID: 14675262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel fluoronucleoside analog NCC inhibits lamivudine-resistant hepatitis B virus in a hepatocyte model.
    Zhang J; Wang Y; Peng Y; Qin C; Liu Y; Li J; Jiang J; Zhou Y; Chang J; Wang Q
    Braz J Infect Dis; 2018; 22(6):477-486. PubMed ID: 30586543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.
    Walters KA; Tipples GA; Allen MI; Condreay LD; Addison WR; Tyrrell L
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1936-42. PubMed ID: 12760870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.